

[PDF] Recent Advances in the Treatment of Opioid Use Disorders<https://crimsonpublishers.com/tnn/pdf/TNN.000572.pdf>

Recently three novel long-acting buprenorphine depot or implant formulations have been studied and in part approved for treatment of opioid use disorders: for subcutaneous weekly and monthly application the depot formulations CAM 2038 [Buvidal®], the monthly

Recent Advances in the Treatment of Opioid Use Disorder ...<https://www.researchgate.net/publication/349989769...>

Apr 01, 2021 · Recent Findings Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment

...

PEOPLE ALSO ASK

How is buprenorphine used to treat opioid dependence? ▾

What medications are used to treat opioid addiction? ▾

What kind of drug is Suboxone for opioid dependence? ▾

When to discontinue pharmacotherapy for opioid use disorder? ▾

[Feedback](#)**Recent Advances in the Treatment of Opioid Use Disorder**<https://link.springer.com/article/10.1007/s11916-021-00941-8> ▾

Mar 11, 2021 · Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment (MAT) include office-based methadone maintenance, implantable and monthly injectable buprenorphine, and an extended-release injectable naltrexone.

Author: Sumanth Kuppalli, Raghav Seth, Vwai... Publish Year: 2021

(PDF) Advances in the treatment of opioid use disorders<https://www.researchgate.net/publication/313015254...>

12,700 Results Any time ▾

[PDF] Recent Advances in the Treatment of Opioid Use Disorders

<https://crimsonpublishers.com/tnn/pdf/TNN.000572.pdf>

formulations have been studieD and in part approved for treatment of opioid use disorders. for subcutaneous weekly and monthly application the depot formulations CAM 2038 [Buvinda®], the monthly depot formulation RBP-6000 [Sublocade™] and the six-month buprenorphine implant [Probuphine™].

Recent Advances in the Treatment of Opioid Use Disorder ...

<https://link.springer.com/article/10.1007/s11916-021-00941-8> •

Mar 11, 2021 - Opioid use disorder (OUD) remains a national epidemic with an immense consequence to the United States' healthcare system. Current therapeutic options are limited by adverse effects and limited efficacy. Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment (MAT) ...

Author: Sumanth Kuppali, Raghav Seth, Vwaia. Publish Year: 2021

Search Tools

Turn off Hover Translation (关闭翻译)

PEOPLE ALSO ASK

Which is the best treatment for opioid addiction?	▾
How are opioid use disorders affect the brain?	▾
How is opioid addiction related to acute mortality?	▾
When did opioid addiction become a physical dependence?	▾



64875_Auto_Edited.docx

Quotes Excluded
Bibliography Excluded

4%
CIVILIAN

Match Overview

Rank	Source	Date	Percentage
1	Internet	36 words crawled on 22-Jan-2021 www.thieme-connect.com	3%
2	Crossref	19 words Florence Virapin, Peder Hjelmström, Nicolas Simon, Amine B enayma et al. "What place for prolonged release buprenorph	1%
3	Internet	12 words crawled on 17-Apr-2021 www.dovepress.com	<1%

Name of Journal: *World Journal of Psychiatry*

Manuscript NO: 64875

Manuscript Type: MINIREVIEWS

Recent Advances in the treatment of opioid use disorders - focus on long-acting buprenorphine formulations

Depot buprenorphine in opioid dependence

Michael Soyka, Andreas G. Franke

国内版

国际版

Recent Advances in the treatment of opioid use disorders–focus or



ALL

IMAGES

VIDEOS

11,300 Results

Any time ▾

[PDF] [Recent Advances in the Treatment of Opioid Use Disorders](#)

<https://crimsonpublishers.com/tnn/pdf/TNN.000572.pdf>

Recently three novel long-acting buprenorphine depot or implant formulations have been studied and in part approved for treatment of opioid use disorders: for subcutaneous weekly and monthly application the depot formulations CAM 2038 [Buvidal®], the monthly

[Recent Advances in the Treatment of Opioid Use Disorder ...](#)

<https://link.springer.com/article/10.1007/s11916-021-00941-8> ▾

Mar 11, 2021 · Transdermal buprenorphine (Butrans™) is available in doses between 5 and 20 mcg/h that is used for chronic pain requiring around-the-clock opioid therapy and may be used for OUD treatment in the future . A long-acting buprenorphine implant called Probuphine was approved by the US Food and Drug Administration in 2016 and delivers a steady state of medication over a 6-month period [30•].

Author: Sumanth Kuppalli, Raghav Seth, Vwai... Publish Year: 2021

(PDF) [Advances in the treatment of opioid use disorders](#)

<https://www.researchgate.net/publication/313015254...>

Jan 27, 2017 · PDF | The development of medications for treating persons with opioid use disorders has expanded the number of evidence-based treatment options,... | ...

[Novel Formulations of Buprenorphine for Treatment of ...](#)

<https://focus.psychiatryonline.org/doi/full/10.1176/appi.focus.20180043>



Buprenorphine For Treatmen...

Benefits and Issues with Oral...

Rationale | >

The Drug Addiction Treatment Act of 2000 extended medical treatment of OUD further into the community by allowing patients to be prescribed sublingual buprenorphine by physicians in their offices, as long as the office-based prescribers had received sufficient training (8 hours) to obtain a waiver from the Drug Enforcement Administration (DEA) to legally prescribe buprenorphine for addiction treatment. Sublingual buprenorphine is an inverse mu opioid receptor agonist and a Schedule III narcotic for the tr...

See more on focus.psychiatryonline.org

Cited by: 2

Author: Richard N Rosenthal

Publish Year: 2019